Another study on pediatric high-grade CNS tumors noted variable B7-H3 expression (a potential marker for CAR-T), recommending tumor tissue testing during B7-H3-targeted trials to assess IHC B7-H3 as a biomarker for tailored treatment (125). Here, CD276 is linked to neoplasm.